Drug
Pegbelfermin clinical trials
Also written BMS-986036.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2018 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 5 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Studies
Open first, then newest update. How each study uses Pegbelfermin is read from its arms, and is right about nine times in ten.
Testing it · 12
- Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced TrialsCompletedMeridian Bioscience, Inc.NCT03611101Written as BMS-986036
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCompletedPhase 2Bristol-Myers SquibbNCT03486912Written as BMS-986036
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCompletedPhase 2Bristol-Myers SquibbNCT03486899Written as BMS-986036
- A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT04634149Written as BMS-986036
- A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean ParticipantsWithdrawnPhase 1Bristol-Myers SquibbNCT04649710Written as BMS-986036
- Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled SyringeCompletedPhase 1Bristol-Myers SquibbNCT04493567Written as BMS-986036
- A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedPhase 2Bristol-Myers SquibbNCT02413372Written as BMS-986036
- A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedPhase 2Bristol-Myers SquibbNCT03400163Written as BMS-986036
- A Study of Experimental Medication BMS-986036 Given to Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03445208Written as BMS-986036
- An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney FunctionCompletedPhase 1Bristol-Myers SquibbNCT03674476Written as BMS-986036
- A Study to Evaluate BMS-986036 in Obese Adults With Type-2 DiabetesCompletedPhase 2Bristol-Myers SquibbNCT02097277Written as BMS-986036
- A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese SubjectsCompletedPhase 1Bristol-Myers SquibbNCT03198182Written as BMS-986036
Codes
What other systems call Pegbelfermin · ClinicalTrials.gg INT001058
- MeSH (NLM) C000630067PegbelferminOne source NLM
- UNII (FDA) P5T1E46W5DPEGBELFERMINConfirmed FDA, NLM
- NCI Thesaurus C174833PegbelferminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630067 | Pegbelfermin | One source NLM |
| UNII (FDA) | P5T1E46W5D | PEGBELFERMIN | Confirmed FDA, NLM |
| NCI Thesaurus | C174833 | Pegbelfermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.